Therapeutic Potential of Carbonic Anhydrase Inhibitors. | [Pakistan Journal of Pharmaceutical Sciences • 2019]

Author(s):

1. Sumbal Bibi: Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Pakistan

2. Tariq Javed: Department of Pharmacy, LMDC, University of Health Sciences Lahore, Punjab, Pakistan

3. Fiaz Alam: Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Pakistan

4. Atif Ali: Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Pakistan

5. Ziaur Rehman Qureshi: Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Pakistan

6. Sayyad Ali: Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Pakistan

7. Majeed Ullah: Department of Pharmacy, Kohat University of Science and Technology(KUST), Kohat, KPK, Pakistan

8. Muhammad Hassham Hassan Bin Asad: Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Pakistan; Kazan (Volga Region) Federal University, Institute of Fundamental Medicine and Biology, Department of Genetics, Kremlevskaya Street, Kazan, Tatarstan, Russia; Laboratory INSERM UMR, Aix-Marseille University, Parc Scientifique et Technologique de Luminy, Avenue de Luminy, Bâtiment TPR2, Case 939, Marsikueille, France

9. Syed Muhammad Farid Hasan: Department of Pharmaceutics, Faculty of Pharmacy, Karachi University, Karachi, Sind, Pakistan

10. Jean Marc Sabatier: Laboratory INSERM UMR, Aix-Marseille University, Parc Scientifique et Technologique de Luminy, Avenue de Luminy, Bâtiment TPR2, Case 939, Marsikueille, France

11. AlbertA Rizvanov: Kazan (Volga Region) Federal University, Institute of Fundamental Medicine and Biology, Department of Genetics, Kremlevskaya Street, Kazan, Tatarstan, Russia

12. Shafiq ur Rahman: Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Pakistan

Abstract:

Enzymes are biological catalyst involve in different biochemical reactions. But over activation of these biomolecules can cause disease thus different inhibitors and knockout therapies are use in current clinical practice. Carbonic anhydrases (CAs), a group of ubiquitously expressed metalloenzymes, are involved in numerous physiological and pathological processes, including gluconeogenesis, lipogenesis, ureagenesis, tumorigenicity and the growth and virulence of various pathogens. In addition to the established role of CA inhibitors (CAIs) as diuretics and antiglaucoma drugs, it has recently emerged that CAIs could have potential as novel anti-obesity, anticancer and anti-infective drugs. Furthermore, recent studies suggest that CA activation may provide a novel therapy for Alzheimer's disease. This article discusses the biological rationale for the novel uses of inhibitors or activators of CA activity in multiple diseases, and highlights progress in the development of specific modulators of the relevant CA isoforms, some of which are now being evaluated in clinical trials.

Page(s): 709-720

DOI: DOI not available

Published: Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 32, Issue: 2, Year: 2019

Keywords:

Keywords are not available for this article.

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views